AngioDynamics

ANGO

Medical - Instruments & Supplies · Healthcare

Price

$13.51

-0.63 (-4.46%)

Market Cap

$558.4M

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+6.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 39.0M (2022) → 41.5M (2026)

AngioDynamics makes medical devices used by doctors to treat cancer and vascular diseases. Its products include tools for removing blood clots, draining fluids, and destroying tumors using heat or electrical energy. The company sells mainly to hospitals and outpatient clinics across the United States.

AngioDynamics earns revenue by selling its devices directly to healthcare facilities, with no major subscription component. It operates primarily in the U.S. but has some international sales, and it competes against larger medical device companies like Becton Dickinson and Medtronic. The company is currently unprofitable, with negative operating and returns on capital, and its key challenge is growing its newer tumor-destruction technology fast enough to offset declining sales in its older vascular product lines.

Winston Score History

Politician Trades

1 trades / 12mo

0 Congressional buys and 1 sell on ANGO in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+8.9% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-72.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$29M/ year

↑ Rising (+12% vs prior year)

9.2% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

11.5%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~2 years

$38M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$38M cash & investments at current burn rate

Growth context

AngioDynamics is growing revenue at 9% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

52.9%

Healthy — 52.9% gross margin

Operating Margin

-8.2%

Losing money on operations — -8.2%

ROCE

-3.7%

Weak — -3.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+5.2%

Slow sales growth (5.2% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

1.0%

Thin free cash flow (1.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial